Oslo, Norway, April 28, 2022 - Lytix Biopharma AS (Lytix), a clinical-stage
company with an in situ vaccination technology platform targeting cancer
indications, today announces that its abstract has been accepted for poster
presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
in Chicago June 3-7, 2022.

Title: LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in
patients with metastatic soft tissue sarcoma.

Presenter: Morten Nielsen, MD | National Center for Cancer Immune Therapy,
Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Poster Session: Sarcoma
Abstract: 11567
Poster: 471

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358 
E-mail: Oystein.Rekdal@lytixbiopharma.com

Ole Peter Norby, Head of Investor Relations
Phone: +47 412 87 179
Email: ole.peter.nordby@lytixbiopharma.com 

About Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company
developing novel cancer immunotherapies, an area within cancer therapy that is
aimed at activating the patient's immune system to fight cancer. The Company's
technology is based on pioneering research in "host defense peptides" - nature's
first line of defense towards foreign pathogens. Lytix Biopharma's lead product,
LTX-315, is a first-in-class oncolytic molecule representing a new and superior
in situ therapeutic vaccination principle to boost anti-cancer immunity, with
the potential to be the ideal combination partner with other types of
immunotherapies. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a U.S. based, healthcare-focused investment firm. For more
information, visit www.lytixbiopharma.com.

About LTX-315
LTX-315 is a potential first-in-class oncolytic molecule administered directly
into a tumor to induce immunogenic cell death. The technology is based on
pioneering research in "host defense peptides" - nature's first line of defense
towards foreign pathogens. LTX-315 has demonstrated positive tumor-specific
immune cell responses in multi-indication Phase I/II oncology trials.

About in situ vaccination 
In situ vaccination stimulates a patient's immune system by injecting drugs with
the ability to kill cancer cells straight into the tumor environment. Lytix
Biopharma has applied this approach with its first-in-class oncolytic molecules,
representing an alternative and unique approach to cancer vaccination.
Importantly, this approach generates an immune response against a broad antigen
repertoire without pre-identifying the antigens, which in turn can save
considerable costs and valuable time.